Assembly flop sees it pivot from curative to chronic hep B focus
Nov 06, 2020 - FierceBiotech
Assembly Bio was hoping its experimental hepatitis B drug could be a functioning cure for the viral liver disease, but a midstage flop has seen the biotech rethink this path in the near term.
The Californian biotech had been running an open-label phase 2 test for vebicorvir (VBR) in chronic hep B patients alongside a nucleos(t)ide analogue reverse transcriptase inhibitor (NrtI).
The idea was that you could treat patients with this combo for 12 to 18 months, take them off therapy and...
Sign up today to gain access to 5 free articles a month from over 200 top subscription outlets.
Are you ready to take your business development to the next level with RelSci Professional?
Nurture your network with daily alerts that notify you when your relationships make news
Map your relationships to any target or prospect to identify a warm introduction
Access unlimited deep dossiers on over 8 million decision makers
Best of all, you can try out all these powerful business development tools absolutely free for 30 days!
Check out News Home to stay on top of the people and organizations you care most about.
